Compare GEO & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GEO | ELVN |
|---|---|---|
| Founded | 1984 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.2B |
| IPO Year | 1996 | 2020 |
| Metric | GEO | ELVN |
|---|---|---|
| Price | $26.82 | $41.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 14 |
| Target Price | $39.00 | ★ $73.92 |
| AVG Volume (30 Days) | ★ 2.0M | 1.2M |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 727.27 | 3.17 |
| EPS | ★ 0.65 | N/A |
| Revenue | ★ $2,263,420,000.00 | N/A |
| Revenue This Year | $13.78 | N/A |
| Revenue Next Year | $8.73 | N/A |
| P/E Ratio | $42.51 | ★ N/A |
| Revenue Growth | ★ 3.85 | N/A |
| 52 Week Low | $12.51 | $14.79 |
| 52 Week High | $33.17 | $62.32 |
| Indicator | GEO | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 33.22 | 40.50 |
| Support Level | $22.29 | $38.58 |
| Resistance Level | $32.56 | $43.05 |
| Average True Range (ATR) | 1.38 | 1.90 |
| MACD | -0.43 | 0.49 |
| Stochastic Oscillator | 10.84 | 47.72 |
The GEO Group Inc specializes in detention facilities and community reentry centers. It operates in four segments: U.S. Secure Services, which mainly encompasses U.S.-based secure services business; Electronic Monitoring and Supervision Services, which conducts its services in the United States, represents services provided to adults for monitoring services and evidence-based supervision and treatment programs for community-based parolees, probationers, and pretrial defendants; Reentry Services conducts its services in the United States represents services provided to adults for residential and non-residential treatment, educational and community-based programs, pre-release and half-way house programs; and International Services. The company operates in U.S, Australia and South Africa.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.